Citations

Showing 10 of 108119 citations.

Fat-Free Mass Index in a Diverse Sample of Male Collegiate Athletes
Currier, Brad S. , Harty, Patrick S. , Zabriskie, Hannah A. , Stecker, Richard A., Moon, Jessica M. , Harty, Patrick S , Zabriskie, Hannah A , Currier, Bradley S , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Journal of Strength and Conditioning Research | April 13, 2019 | Volume: 33 | Issue: 6 | Pages: 1474-1479

10.1519/jsc.0000000000003158 | PMID 30985525 Get It

Abstract Currier, BS, Harty, PS, Zabriskie, HA, Stecker, RA, Moon, JM, Jagim, AR, and Kerksick, CM. Fat-free mass index in a diverse sample of male collegiate athletes. J Strength Cond Res 33(6): 1474–1479, 2019—Fat-free mass index (FFMI) is a body composition metric that has been used to assess relative muscularity in athletes. Fat-free mass index is calculated by dividing FFM by height squared, although further height corrections through linear regression may be needed in taller individuals. This study reported height-adjusted FFMI (FFMI Adj ) data in 209 male collegiate athletes from 10 sports (baseball, cross country, football, golf, ice hockey, weightlifting, rugby, swimming, track and field, and water polo) and the FFMI Adj natural upper limit for sports with sufficient sample size. The body composition of all subjects (mean ± SD ; age: 20.7 ± 1.9 years, height: 182.9 ± 6.7 cm, body mass: 90.8 ± 16.8 kg, and percent body fat: 15.6 ± 5.3) was measured using dual-energy x-ray absorptiometry. Linear regression was used to adjust for height, and the FFMI Adj natural upper limit was determined by calculating the 97.5th percentile of all values. One-way analyses of variance with Games-Howell post hoc comparisons were used to determine between-sport differences. A paired-samples t -test revealed a significant difference ( p < 0.001) between unadjusted and adjusted mean FFMI values. The overall mean FFMI Adj was 22.8 ± 2.8 kg·m −2 . Significant between-sport differences ( p < 0.001) in FFMI Adj were identified. Average FFMI Adj was highest in football athletes (24.28 ± 2.39 kg·m −2 ) and lowest in water polo athletes (20.68 ± 3.56 kg·m −2 ). The FFMI Adj upper limit was calculated for all athletes (28.32 kg·m −2 ), rugby (29.1 kg·m −2 ), and baseball (25.5 kg·m −2 ). This study reported FFMI Adj values in a diverse cohort of male collegiate athletes, providing data for the first time in several sports. These values can be used to guide nutritional and exercise interventions, predict athletic performance, and provide coaches with standardized information regarding the potential for further FFM accretion in male athletes.
Cutaneous lesions of angioimmunoblastic T‐cell lymphoma: Clinical, pathological, and immunophenotypic features
Sartori‐Valinotti, Julio C. , Wada, David A., He, Rong , Cappel, Mark A. , Feldman, Andrew L. , Oishi, Naoki , Sartori-Valinotti, Julio C., Feldman, Andrew L , Bennani, N. Nora

Mayo Clinic

Journal of Cutaneous Pathology | April 13, 2019 | Volume: 46 | Issue: 9 | Pages: 637-644

10.1111/cup.13475 | PMID 30980412 Get It

AbstractBackgroundAngioimmunoblastic T‐cell lymphoma (AITL) is a systemic peripheral T‐cell lymphoma with a follicular helper T‐cell (TFH) immunophenotype that frequently involves the skin. However, the histopathology of cutaneous involvement by AITL has not been fully established.MethodsWe reviewed the clinicopathological features of 19 patients seen at our institution with AITL involving the skin. Pan‐T‐cell and TFH marker expression was evaluated by immunohistochemistry. Epstein‐Barr virus (EBV) was detected using in situ hybridization (ISH) for Epstein‐Barr virus‐encoded small RNA (EBER). T‐cell receptor (TCR) gene rearrangement was evaluated by PCR.ResultsAITL affected both trunk and extremities in 15/19 cases (79%). Perivascular infiltration by small and/or medium‐sized lymphocytes was seen in 18/19 (95%). Granulomatous inflammation was identified in 4/19 (21%). Aberrant loss of CD2, CD5, or CD7 was identified in 1/18 (6%), 2/18 (11%), or 7/19 (37%) cases, respectively. Seventeen of eighteen evaluable cases (95%) expressed 2 to 3 TFH markers: PD‐1 in 19/19 (100%), BCL6 in 94% (17/18), and CD10 in 37% (7/19). EBV‐positive cells were detected in 3/18 (17%) with varying density. Clonal TCR gene rearrangement was identified in 9/11 (82%).ConclusionsCutaneous involvement by AITL shows relatively non‐specific histopathological features. However, an immunohistochemical panel including TFH markers and EBER ISH is useful in differential diagnosis.
Treatment of Nonmetastatic Breast Cancer
Ruddy, Kathryn J. , Ganz, Patricia A.

Mayo Clinic

JAMA | April 12, 2019 | Volume: 321 | Issue: 17 | Pages: 1716

10.1001/jama.2019.3927 | PMID 30977769 Get It

Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary
Turner, Dan , Wilson, David C. , Mould, Diane R. , Baldassano, Robert N. , Dubinsky, Marla C. , Heyman, Melvin B. , Ridder, Lissy de , Hyams, Jeffrey S. , Carpi, Javier Martín de , Conklin, Laurie S. , Faubion, William A. , Koletzko, Sibylle , Bousvaros, Athos, Ruemmele, Frank M. , Ruemmele, Frank M , Griffiths, Anne Marie , Russell, Richard Kay

Mayo Clinic

Gut | April 12, 2019 | Volume: 69 | Issue: 1 | Pages: 32-41

10.1136/gutjnl-2018-317987 | PMID 30979718 Get It

Introduction The optimal trial design for assessing novel therapies in paediatric IBD (PIBD) is a subject of intense ongoing global discussions and debate among the different stakeholders. However, there is a consensus that the current situation in which most medications used in children with IBD are prescribed as off-label without sufficient paediatric data is unacceptable. Shortening the time lag between adult and paediatric approval of drugs is of the upmost importance. In this position paper we aimed to provide guidance from the global clinical research network (Pediatric Inflammatory Bowel Disease Network, PIBDnet) for designing clinical trials in PIBD in order to facilitate drug approval for children. Methods A writing group has been established by PIBDnet and topics were assigned to different members. After an iterative process of revisions among the writing group and one face-to-face meeting, all statements have reached consensus of >80% as defined a priori. Next, all core members of PIBDnet voted on the statements, reaching consensus of >80% on all statements. Comments from the members were incorporated in the text. Results The commentary includes 18 statements for guiding data extrapolation from adults, eligibility criteria to PIBD trials, use of placebo, dosing, endpoints and recommendations for feasible trials. Controversial issues have been highlighted in the text. Conclusion The viewpoints expressed in this paper could assist planning clinical trials in PIBD which are both of high quality and ethical, while remaining pragmatic.
55 Poor sleep quality assessed subjectively associated with worsening SLE disease activity
Hinze, Alicia M. , Chu, Philip , Sen, Deepali, Ju, Yo‐El S. , Chu, Philip, Al‐Hammadi, Noor , Kim, Alfred H.J.

Mayo Clinic

Abstracts | April 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: A40.2-A41

10.1136/lupus-2019-lsm.55 Get It

189 Epidemiology of antiphospholipid syndrome: a population-based study
Pham, Michael M. , Crowson, Cynthia S. , Moder, Kevin G., Pruthi, Rajiv K. , Matteson, Eric L. , Duarte‐García, Alí , Warrington, Kenneth J.

Mayo Clinic

Abstracts | April 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: A143.1-A143

10.1136/lupus-2019-lsm.189 Get It

112 Trends in treatment of systemic lupus erythematosus and lupus nephritis: 2006–2016
Crowson, Cynthia S. , Vaidehi, Chowdhary, Amin, Shreyasee , Matteson, Eric L. , Shah, Nilay , Duarte‐García, Alí , Warrington, Kenneth J. , Shah, Nilay

Mayo Clinic

Abstracts | April 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: A83-A84

10.1136/lupus-2019-lsm.112 Get It

Communication of Recommendations for the Disposal of Unused Prescription Opioid Medications by Stakeholders in the News Media
Petrik, Megan , McNamara, Patrick J. , Moeschler, Susan M. , Blair, Benjamin

Mayo Clinic

Pain Medicine | April 12, 2019 | Volume: 20 | Issue: 9 | Pages: 1711-1716

10.1093/pm/pnz104 | PMID 31127840 Get It

Abstract Objective The opioid epidemic is a national public health emergency that requires a comprehensive approach to reduce opioid-related deaths. Proper and timely disposal of unused prescription opioids is one method to deter improper use of these medications and prevent overdose. The objective of this study was to understand how recommendations for disposing of unused prescription opioids, including both take-back programs and toilet disposal, are communicated to the public. Methods Two hundred sixty-three US newspaper articles published between January 1, 2014, and June 30, 2017, containing information on opioids and take-back programs were found using LexisNexis. Using content analysis, articles were coded for the presentation of and recommendation for opioid disposal practices, beliefs about environmental harm from toilet disposal, and additional strategies to reduce opioid supply. The entity responsible for the statement was also captured. Results Take-back programs were presented as a recommended disposal strategy for unused prescription opioids in 88.6% of coded articles. Toilet disposal was presented as a recommended disposal strategy for unused prescription opioids in 3.4% of articles and as harmful to the environment in 16.0% of articles. Individuals from health care, government, and law enforcement were primarily involved in discussing opioid disposal practices. Conclusions Although toilet disposal is recommended by the US Food and Drug Administration (FDA) for disposal of unused prescription opioids when a take-back program is not readily available, it was infrequently presented or recommended in news media articles. These results highlight the importance of improving communication of FDA guidelines for opioid disposal in the media, particularly by health care providers, government employees, and law enforcement officials.
Faculty Opinions recommendation of Prodromal Parkinson's Disease: The Decade Past, the Decade to Come.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735412979.793558575 Get It

Impact of hospitalists on the efficiency of inpatient care and patient satisfaction: a systematic review and meta-analysis
Salim, Sohail Abdul , Elmaraezy, Ahmed , Pamarthy, Amaleswari, Thongprayoon, Charat , Palabindala, Venkataraman , Cheungpasitporn, Wisit , Thongprayoon, Charat , Cheungpasitporn, Wisit

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | April 12, 2019 | Volume: 9 | Issue: 2 | Pages: 121-134

10.1080/20009666.2019.1591901 | PMID 31044043 Get It